(A) Leronlimab was well-tolerated with 5 grade (1) and 2 grade (2) treatment-related adverse events (TRAES).
(
(C) NO dose limiting Toxicities were observed up to 700mg dose.
(D) among the subset of patients who received Leronlimab @ a dose of 525mg or 700mg QW SC 88% (n= 15/17)
Here it comes...significantly Upregulated PD-L1 in circulating cells.
The presenting author, Dr. Dolezal is an advisor to Cytodyn,Inc.
Contact email: milanad@stanford.edu
That should answer a few questions